REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026TRENDINGHexarelin: ↑↑ Surging ��� Trends score 100 as of May 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingEVENTpep-talk con ��� First US Peptide Convention · August 2026 · Anaheim CAFDAFDA advisory committee meetings scheduled: late July 2026REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026TRENDINGHexarelin: ↑↑ Surging ��� Trends score 100 as of May 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingEVENTpep-talk con ��� First US Peptide Convention · August 2026 · Anaheim CAFDAFDA advisory committee meetings scheduled: late July 2026

For research purposes only. Full disclaimer →

Research/Paper
Back to Research Library
PubMedPreclinical

Skin-adaptive film dressing with smart-release of growth factors accelerated diabetic wound healing.

Zhao Yingzheng, Huang Lantian, Lin Gaolong, Tong Mengqi, Xie Yilin, Pan Hanxiao, Shangguan Jianxun, Yao Qing, Xu Shihao, Xu Helin
International journal of biological macromolecules2022DOI: 10.1016/j.ijbiomac.2022.10.054
KPVEGF

Quality Score

4/10

Citations

0

Subjects

Non-Human

PeptideVault Analysis

Study Design

Preclinical research is the foundation of the drug development pipeline. While these findings require human validation, they establish the mechanistic basis that informs dosing strategies, safety profiles, and target identification for future clinical work.

Our Assessment

Quality Assessment: 4/10 — This study contributes useful data but has methodological limitations that warrant caution. The findings are suggestive rather than definitive, and we'd recommend looking for corroborating evidence before drawing strong conclusions.

Findings in Context

The results for KPV, EGF are encouraging.

On the Limitations

Every study has limitations, and being transparent about them is what separates good science from hype. These limitations don't invalidate the findings — they define the boundaries of what we can confidently conclude.

The Takeaway

Bottom line: Early-stage evidence for KPV, EGF. Interesting mechanistic insights, but we'll need human data before drawing practical conclusions.

Key Findings

The study developed a skin-adaptive three-layered film dressing that releases anti-inflammatory tripeptide KPV and epidermal growth factor EGF in response to wound conditions, demonstrating significant improvement in diabetic mouse wound healing through mechanisms of inflammatory inhibition, angiogenesis, and collagen deposition.

Limitations

The research is limited to preclinical studies using mice, which may not fully translate to human clinical settings. Additionally, the study focuses on a specific model of diabetes and wound healing, limiting generalizability.

Citation

Zhao Yingzheng, Huang Lantian, Lin Gaolong et al.. (2022). Skin-adaptive film dressing with smart-release of growth factors accelerated diabetic wound healing.. International journal of biological macromolecules. https://doi.org/10.1016/j.ijbiomac.2022.10.054

View full text on PubMed

Related Papers

This content is derived from peer-reviewed research for educational purposes only. It does not constitute medical advice. Always consult a qualified healthcare provider before using any peptide-based therapy.